Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13684182 | 0.86 | — | — | |
| SCHEMBL783215 | 0.71 | PIK3CD (0.64) | PIK3CDAR | |
| SCHEMBL12569937 | 0.69 | — | — | |
| SCHEMBL1032637 | 0.68 | PIK3CD (0.46) | PIK3CDAR | |
| Iodide SCHEMBL8537763 | 0.67 | — | — | |
| SCHEMBL9914394 | 0.66 | — | — | |
| SCHEMBL13684183 | 0.63 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL10132034 | 0.63 | NOTUM (0.51) | AR | |
| SCHEMBL15188382 | 0.62 | — | — | |
| SCHEMBL13684736 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382265-B2 | Oxazolidone compound, preparing method and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-07-05 | — | — | US | disclosed |
| US-20150361091-A1 | OXAZOLIDONE COMPOUND, PREPARING METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-12-17 | — | — | US | disclosed |
| US-7589204-B2 | Indane compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589207-B2 | Cyclohexyl compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-7569579-B2 | for inhibition of HIV replication and treatment of acquired immune deficiency syndrome | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090187021-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | YOUNGMAN MICHAEL | 2009-07-23 | — | — | US | disclosed |
| US-7531661-B2 | Indane compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090187021-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | CCR5, CCL5, IDO1 | PIK3CD 2423/4885AR 1766/4885 |
| US-20150361091-A1 | OXAZOLIDONE COMPOUND, PREPARING METHOD AND APPLICATION THEREOF | CYP3A43, CYP2C9, F2 | PIK3CD 2305/4885AR 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.